ClinicalTrials.gg
CompletedNCT01727986Updated May 5, 2016

An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study

A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 4 sites in Brazil. Open to participants aged 9 Years to 18 Years. Per ClinicalTrials.gov, last updated 2016-05-05.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Ages
9 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.

Enrollment
16th of 21
11 · median 52
Started
2013
with 4 others
Phase 3
12 of 21
1 open now
Registered
13th of 21
by date
Lead sponsor
12 of 21
Hoffmann-La Roche

Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 16th largest by enrollment, is one of 5 that started in 2013, is one of 12 in phase 3, and was the 13th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 9 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tocilizumab in Arthritis, Juvenile, or all of them as a file.
02

Study summary

This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study. Patients aged 9-18 years with at least JIA ACR30 clinical response to RoActemra/Actemra in the core study will be eligible to receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
9 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 9 to 18 years of age who completed visit 33 (week 104) of WA19977 study with at least JIA ACR30 clinical response to RoActemra/Actemra relative to baseline in WA19977, with no AEs, SAEs or conditions that lead to unacceptable risk of continued treatment
  • Females of and males with female partners of child-bearing potential must agree to use effective as defined by protocol

Exclusion criteria

Exclusion Criteria:

  • Patients with, according to investigator judgment, not satisfactory benefit from RoActemra/Actemra therapy within WA19977
  • Treatment with any agent since the last administration of study drug in the core study WA19977 or current participation in another clinical trial except WA19977
  • Patient developed any other rheumatic disease or overlap syndrome other than the permitted polyarticular-course JIA subsets: rheumatoid factor positive or negative JIA or extended oligoarticular JIA
  • Patient is pregnant , lactating, or intending to become pregnant during the study and up to 12 weeks after the last administration of study drug
  • Any significant concomitant disease or medical or surgical condition
  • History of significant allergic or infusion reactions to prior biologic therapy
  • Currently active primary or secondary immunodeficiency
  • Current abuse of alcohol, drugs or chemical abuse
  • Known and currently active acute, subacute, chronic infections or history of recurrent infection; patients suffering from ongoing active infections with Epstein Barr virus, herpes zoster or recurrent history of urinary tract infection can be included after the (acute) infection has been excluded or subsided
  • Positive for latent tuberculosis (TB)
  • Currently active asthma for which the patient has required the use of oral or parenteral for >/= 2 weeks within 6 months prior to entering the study
  • Inadequate hepatic, renal or bone marrow function
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    RoActemra/Actemra

    Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks

06

What researchers measure

Primary outcomes

  1. Long-term safety: Incidence of adverse events

    Time frame: approximately 3 years

Secondary outcomes

  1. Response rates according to the American College of Rheumatology criteria for juvenile idiopathic arthritis (JIA ACR)

    Time frame: approximately 3 years

  2. Proportion of patients achieving inactive disease/clinical remission

    Time frame: approximately 3 years

07

Study locations

4 sites
  • Rio de janeiro, RJ 20551030, Brazil
  • Rio de Janeiro, RJ 21941-912, Brazil
  • Porto Alegre, RS 90035-003, Brazil
  • Sao Paulo, SP 05403-000, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2012
First posted
Nov 16, 2012
Start
Mar 2013
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Last update
May 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01727986
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 16, 2012
Start date
Mar 2013
Primary completion
Nov 2015
Completion
Nov 2015
Last update
May 5, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion